Scarica l'app Stockscreener
0.0692
26.38%
-0.0248
Dopo l'orario di chiusura:
.07
0.0008
+1.16%
Precedente Chiudi:
$0.094
Aprire:
$0.083
Volume 24 ore:
9.39M
Relative Volume:
1.95
Capitalizzazione di mercato:
$3.79M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-26.38%
1M Prestazione:
-30.80%
6M Prestazione:
-92.31%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.068
$0.0836
Intervallo di 1 settimana:
$0.068
$0.107
Portata 52W:
$0.068
$4.31
Psyence Biomedical Ltd Stock (PBM) Company Profile
Nome
Psyence Biomedical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Psyence Biomedical Ltd Borsa (PBM) Ultime notizie
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs - Yahoo Finance
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs - The Manila Times
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs - StockTitan
Where Do Analysts See Psyence Biomedical Ltd. (NASDAQ: PBM) Heading? - Stocks Register
Bullish Prospects For Psyence Biomedical Ltd. (NASDAQ: PBM) Shares In 2024 - Stocks Register
Natural Gas LDay (F) (HHM19) Quote - The Globe and Mail
Psyence Biomed adds Australian site for psilocybin trial - Investing.com
Psyence Biomed adds Australian site for psilocybin trial By Investing.com - Investing.com South Africa
Psyence Biomed Announces Recruitment of Second Clinical - GlobeNewswire
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care - StockTitan
Psyence Biomedical Sets Annual General Meeting for November 12 - Investing.com
Psyence Biomedical Plans Key Shareholder Meeting - TipRanks
Psyence Biomedical Sets Annual General Meeting for November 12 By Investing.com - Investing.com UK
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development - The Manila Times
Psyence Biomedical Ltd. (PBM) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
How analysts predict Psyence Biomedical Ltd. (PBM) will perform this quarter? - US Post News
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical - The Manila Times
Gaining Ground: Psyence Biomedical Ltd. (PBM) Closes Higher at 0.10, Up 5.70 - The Dwinnex
What is Psyence Biomedical Ltd. (PBM) Stock Return on Shareholders’ Capital? - SETE News
Psyence Biomedical Ltd. [PBM] is -98.82% lower this YTD. Is it still time to buy? - The DBT News
Investor Alert: What’s Really Going On At Psyence Biomedical Ltd. (NASDAQ: PBM) - Stocks Register
There is no way Psyence Biomedical Ltd. (PBM) can keep these numbers up - SETE News
Psyence Biomedical Converts Debt to Equity - TipRanks
PBM’s Stock Journey: What Investors Need to Know About Psyence Biomedical Ltd.’s Performance - The InvestChronicle
Is it possible to buy Psyence Biomedical Ltd.(PBM) shares at a good price now? - US Post News
Financial Analysis: Psyence Biomedical Ltd. (PBM)’s Ratios Unveil Key Insights - The Dwinnex
PBMPsyence Biomedical Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Psyence Biomed halts Clairvoyant Therapeutics acquisition - Investing.com
Psyence Biomed halts Clairvoyant Therapeutics acquisition By Investing.com - Investing.com UK
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant - The Manila Times
Views of Wall Street’s Leading Experts on Psyence Biomedical Ltd. - SETE News
Psyence Biomedical Ltd. (PBM) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Momentum: Psyence Biomedical Ltd. (PBM) Registers a -1.10 Decrease, Closing at 0.11 - The Dwinnex
Psyence Biomedical Ltd. (PBM) stock analysis: A comprehensive overview - US Post News
Psyence Biomedical Ltd. (PBM): Be Patient, You Will Learn - Stocks Register
An analyst sees good growth prospects for Psyence Biomedical Ltd. (PBM) - SETE News
A stock that deserves closer examination: Psyence Biomedical Ltd. (PBM) - US Post News
Stock Performance Spotlight: Psyence Biomedical Ltd. (PBM) Ends the Day at 0.12, Down by -6.11 - The Dwinnex
Psyence Group Sells Stake to Psyence Biomedical - TipRanks
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs - Yahoo Finance
Psyence Biomed acquires stake in PsyLabs for $1.1 million By Investing.com - Investing.com Canada
Psyence Biomed acquires stake in PsyLabs for $1.1 million - Investing.com
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs - StockTitan
Psyence inks several deals to expand psilocybin research, footprint - Green Market Report
A new trading data show Psyence Biomedical Ltd. (PBM) is showing positive returns. - SETE News
Psyence Biomedical Ltd. (PBM) Stock: A Year of Declines and Increases - The InvestChronicle
Balance Sheet Insights: Psyence Biomedical Ltd. (PBM)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Psyence Biomedical Trials Psilocybin for Palliative Care - TipRanks
Psyence CEO says positioned ‘to be a leader’ in psychedelic-based therapeutics - TipRanks
Psyence Biomedical Ltd. (PBM) did well last session? - US Post News
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones - StockTitan
Psyence Biomedical Ltd Azioni (PBM) Dati Finanziari
Non sono disponibili dati finanziari per Psyence Biomedical Ltd (PBM). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):